3rdPartyFeeds

CLASS ACTION UPDATE for JELD, CRON and ANAB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 12, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ... Read More...
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / April 12, 2020 / Levi &amp; Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / April 12, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="JELD Shareholders Click Here: https://www.zlk.com/pslra-1/jeld-wen-holding-inc-loss-form?prid=6004&amp;wire=1
CRON Shareholders Click Here: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=6004&amp;wire=1
ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6004&amp;wire=1” data-reactid=”13″>JELD Shareholders Click Here: https://www.zlk.com/pslra-1/jeld-wen-holding-inc-loss-form?prid=6004&wire=1
CRON Shareholders Click Here: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=6004&wire=1
ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6004&wire=1

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="* ADDITIONAL INFORMATION BELOW *” data-reactid=”14″>* ADDITIONAL INFORMATION BELOW *

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Jeld-Wen Holding, Inc. (JELD)” data-reactid=”15″>Jeld-Wen Holding, Inc. (JELD)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="JELD Lawsuit on behalf of: investors who purchased January 26, 2017 – October 15, 2018
Lead Plaintiff Deadline : April 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/jeld-wen-holding-inc-loss-form?prid=6004&amp;wire=1” data-reactid=”16″>JELD Lawsuit on behalf of: investors who purchased January 26, 2017 – October 15, 2018
Lead Plaintiff Deadline : April 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/jeld-wen-holding-inc-loss-form?prid=6004&wire=1

According to the filed complaint, during the class period, Jeld-Wen Holding, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s products, including doors, did not compete against other manufacturers on price, contrary to Jeld-Wen’s representations; (2) the market in which the Company sells its doors is not “highly competitive” as the Company claimed; (3) Jeld-Wen’s strong margins and anticipated margin growth were not, as the Company claimed, attributed to changes they had made in Jeld-Wen’s business operations and strategies; and (4) Jeld-Wen failed to disclose the Company’s anti competitive conduct. Because of the foregoing, Defendants’ statements about the Company’s business, operations and prospects lacked a reasonable basis.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Cronos Group Inc. (CRON)” data-reactid=”18″>Cronos Group Inc. (CRON)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CRON Lawsuit on behalf of: investors who purchased May 9, 2019 – March 2, 2020
Lead Plaintiff Deadline : May 11, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=6004&amp;wire=1” data-reactid=”19″>CRON Lawsuit on behalf of: investors who purchased May 9, 2019 – March 2, 2020
Lead Plaintiff Deadline : May 11, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=6004&wire=1

According to the filed complaint, during the class period, Cronos Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company’s ability to timely file its periodic reports; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="AnaptysBio, Inc. (ANAB)” data-reactid=”21″>AnaptysBio, Inc. (ANAB)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline : May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6004&amp;wire=1” data-reactid=”22″>ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline : May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6004&wire=1

According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company’s Phase 2a trial in atopic dermatitis, including the timing and extent of patients’ use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company’s statements omitted key information from the Company’s Phase 2a trial in peanut allergy, including patients’ average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company’s decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants’ positive statements about the efficacy and prospects of AnaptysBio’s lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.” data-reactid=”24″>You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Read More

Add Comment

Click here to post a comment